Vasilios Voudouris

Dr. Vasilios Voudouris


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2025 in Cancers
Verified
Journal Article
Open access
PDF file
DFDimitrios Filioglou
Dimitrios Filioglou
NSNina Santa-Cruz
Nina Santa-Cruz
GLGeovana S. F. Leite
Geovana S. F. Leite
DDDan W. Davini
Dan W. Davini
MCMegan J. Cracchiolo
Megan J. Cracchiolo
Emmanuel KatsanisEmmanuel Katsanis
Emmanuel Katsanis
Background/Objectives: Bendamustine (BEN) combined with rituximab (RTX) remains a standard first-line therapy for transplant-ineligible patients with newly diagnosed mantle cell lymphoma (MCL). Meanwhile, novel targeted therapies such as Bruton tyrosine kinase inhibitors (BTKis) are increasingly used in the treatment of relapsed/refractory (R/R) MCL. We recently reported that a novel oral formulation of BEN exhibits comparable efficacy to the intravenous counterpart. In this study, we investigated the efficacy of oral BEN administered alone or in combination with the oral BCL-2 inhibitor Venetoclax (VEN) and/or the oral BTKi Acalabrutinib (ACAL), against two human MCL cell lines (Jeko-1 and Z-138) representative of the R/R disease subtype. Methods: We performed in vitro analyses using MTS viability and Annexin V/PI apoptosis assays. For the in vivo studies, all treatments were administered via oral gavage in xenograft mouse models. Therapeutic efficacy was evaluated by monitoring tumor growth and survival. Results: BEN induced significant cytotoxicity in both cell lines at low, clinically relevant concentrations. In contrast, VEN demonstrated limited efficacy as monotherapy, with Z-138 showing sensitivity only at high doses. However, combining BEN with VEN with or without ACAL, enhanced apoptosis and cytotoxicity, with more pronounced effects in Z-138. In vivo, oral BEN significantly reduced tumor growth and prolonged survival in both xenograft models. In the Z-138 model, the addition of VEN ± ACAL further improved survival outcomes. Conclusions: Our findings support the efficacy of oral BEN as both a monotherapy and as part of an all-oral treatment regimen for MCL. These results warrant further investigation into the clinical potential of oral BEN, particularly in combination with targeted agents.

19 May 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
DFDimitrios Filioglou
Dimitrios Filioglou
NSNina Santa-Cruz
Nina Santa-Cruz
GLGeovana Sf Leite
Geovana Sf Leite
DDDan W Davini
Dan W Davini
MCMegan J Cracchiolo
Megan J Cracchiolo
Emmanuel KatsanisEmmanuel Katsanis
Emmanuel Katsanis
Bendamustine (BEN) combined with Rituximab (RTX) remains a standard first-line therapy for transplant-ineligible patients with newly diagnosed mantle cell lymphoma (MCL). Meanwhile, novel targeted therapies such as Bruton tyrosine kinase inhibitors (BTKis) are increasingly used in the treatment of relapsed/refractory (R/R) MCL. We recently reported that a novel oral formu-lation of BEN exhibits comparable efficacy to the intravenous counterpart. In this study, we in-vestigated the efficacy of oral BEN administered alone or in combination with the oral BCL-2 in-hibitor Venetoclax (VEN) and/or the oral BTKi acalabrutinib (ACAL), against two human MCL cell lines (Jeko-1 and Z-138) representative of the R/R disease subtype. We performed in vitro analyses using MTS viability and Annexin V/PI apoptosis assays. BEN induced significant cyto-toxicity in both cell lines at low, clinically relevant concentrations. In contrast, VEN demonstrat-ed limited efficacy as monotherapy, with Z-138 showing sensitivity only at high doses. However, combining BEN with VEN with or without ACAL, enhanced apoptosis and cytotoxicity, with more pronounced effects in Z-138. In vivo, oral BEN significantly reduced tumor growth and prolonged survival in both xenograft models. In the Z-138 model, the addition of VEN ± ACAL further improved survival outcomes. Overall, our findings support the efficacy of oral BEN as both a monotherapy and as part of an all-oral treatment regimen for MCL. These results warrant further investigation into the clinical potential of oral BEN, particularly in combination with targeted agents.